ArticleCancer research communications2022

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study.

Yasutoshi Kuboki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.